Published in Int Immunol on April 19, 2004
TLR-based immune adjuvants. Vaccine (2010) 2.10
Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab (2010) 1.94
The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. J Autoimmun (2007) 1.55
Monocytes-macrophages that express α-smooth muscle actin preserve primitive hematopoietic cells in the bone marrow. Nat Immunol (2012) 1.38
G-CSF regulates hematopoietic stem cell activity, in part, through activation of Toll-like receptor signaling. Leukemia (2014) 1.27
Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin Immunopathol (2005) 1.25
Morbillivirus receptors and tropism: multiple pathways for infection. Front Microbiol (2012) 1.18
Regulation of hematopoietic stem cell activity by inflammation. Front Immunol (2013) 1.17
DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. PLoS Pathog (2008) 1.15
Grasping nettles: cellular heterogeneity and other confounders in epigenome-wide association studies. Hum Mol Genet (2014) 0.97
Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells. Clin Exp Immunol (2009) 0.95
Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases. Clin Oral Investig (2014) 0.86
Early events following experimental infection with Peste-Des-Petits ruminants virus suggest immune cell targeting. PLoS One (2013) 0.85
Immunoregulatory profile of monocytes from cutaneous leishmaniasis patients and association with lesion size. Parasite Immunol (2013) 0.84
CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes. Inflamm Res (2013) 0.80
Differential expression of CD150 (SLAM) on monocytes and macrophages in chronic inflammatory contexts: abundant in Crohn's disease, but not in multiple sclerosis. J Clin Pathol (2005) 0.80
Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines. Clin Vaccine Immunol (2014) 0.79
Ouabain affects the expression of activation markers, cytokine production, and endocytosis of human monocytes. Mediators Inflamm (2014) 0.78
Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule. Cancer Sci (2014) 0.78
Contextualization procedure and modeling of monocyte specific TLR signaling. PLoS One (2012) 0.77
Global effect of interleukin-10 on the transcriptional profile induced by Neisseria meningitidis in human monocytes. Infect Immun (2012) 0.77
Physiological aspects of Toll-like receptor 4 activation in sepsis-induced acute kidney injury. Acta Physiol (Oxf) (2016) 0.75
Biological Activity of Masked Endotoxin. Sci Rep (2017) 0.75
Myeloid cells as target of fingolimod action in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm (2015) 0.75
Histamine Regulates Actin Cytoskeleton in Human Toll-like Receptor 4-activated Monocyte-derived Dendritic Cells Tuning CD4+ T Lymphocyte Response. J Biol Chem (2016) 0.75
Intraoperative detection of viable bone with fluorescence imaging using Visually Enhanced Lesion Scope in patients with bisphosphonate-related osteonecrosis of the jaw: clinical and pathological evaluation. Osteoporos Int (2015) 0.75
Human Monocyte Subsets Are Transcriptionally and Functionally Altered in Aging in Response to Pattern Recognition Receptor Agonists. J Immunol (2017) 0.75
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Polymyositis and dermatomyositis. Lancet (2003) 7.24
Astrocytes are active players in cerebral innate immunity. Trends Immunol (2007) 4.08
Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. N Engl J Med (2004) 4.01
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol (2004) 2.39
Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response. Am J Pathol (2003) 2.24
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology (2012) 2.09
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain (2002) 2.02
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 1.80
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med (2008) 1.72
Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol (2010) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet (2011) 1.52
Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol (2007) 1.52
Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. Exp Neurol (2013) 1.46
Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol (2009) 1.40
De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol (2011) 1.35
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 1.33
Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain (2004) 1.32
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol (2013) 1.27
Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol (2011) 1.27
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol (2012) 1.27
Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A (2009) 1.26
Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol (2005) 1.23
Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum (2007) 1.19
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs (2002) 1.16
Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med (2012) 1.15
Latency of alpha-herpes viruses is accompanied by a chronic inflammation in human trigeminal ganglia but not in dorsal root ganglia. J Neuropathol Exp Neurol (2006) 1.15
Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol (2003) 1.15
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
Reconstitution of paired T cell receptor alpha- and beta-chains from microdissected single cells of human inflammatory tissues. Proc Natl Acad Sci U S A (2006) 1.14
Presence of HSV-1 immediate early genes and clonally expanded T-cells with a memory effector phenotype in human trigeminal ganglia. Brain Pathol (2007) 1.11
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med (Berl) (2010) 1.11
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol (2012) 1.11
Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol (2005) 1.10
The emerging role of microRNAs in multiple sclerosis. Nat Rev Neurol (2010) 1.08
Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci U S A (2003) 1.07
Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Eur Neurol (2005) 1.07
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol (2012) 1.06
Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain (2012) 1.06
Humoral autoimmunity in multiple sclerosis. J Neurol Sci (2010) 1.05
Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J Neurol Sci (2008) 1.05
Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med (2013) 1.04
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more. Ther Adv Neurol Disord (2012) 1.03
BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun (2005) 1.02
Revised McDonald criteria: the persisting importance of cerebrospinal fluid analysis. Ann Neurol (2011) 1.02
B cells in MS and NMO: pathogenesis and therapy. Semin Immunopathol (2014) 1.01
The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol (2013) 1.01
Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T. Invest Radiol (2012) 1.01
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics (2007) 1.01
Expression of herpes simplex virus 1-encoded microRNAs in human trigeminal ganglia and their relation to local T-cell infiltrates. J Virol (2011) 1.00
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol (2014) 0.99
HSV-1 genome subnuclear positioning and associations with host-cell PML-NBs and centromeres regulate LAT locus transcription during latency in neurons. PLoS Pathog (2012) 0.98
Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. Nat Med (2012) 0.97
Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation (2011) 0.97
Progress in the treatment of myasthenia gravis. Ther Adv Neurol Disord (2008) 0.96
Dual role of inflammation in CNS disease. Neurology (2007) 0.96
Heart structure-specific transcriptomic atlas reveals conserved microRNA-mRNA interactions. PLoS One (2013) 0.96
Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain (2004) 0.94
Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicol Sci (2012) 0.92
Molecular mimicry in multiple sclerosis. N Engl J Med (2003) 0.92
The role of neurotrophins in muscle under physiological and pathological conditions. Muscle Nerve (2006) 0.91
Latency of herpes simplex virus type-1 in human geniculate and vestibular ganglia is associated with infiltration of CD8+ T cells. J Med Virol (2010) 0.91
Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter. J Immunol (2002) 0.90
Prospects of transcript profiling for mRNAs and MicroRNAs using formalin-fixed and paraffin-embedded dissected autoptic multiple sclerosis lesions. Brain Pathol (2012) 0.90
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol (2005) 0.88
Target specificity of an autoreactive pathogenic human γδ-T cell receptor in myositis. J Biol Chem (2012) 0.88